What You Should KnowDigital healthcare leader iRhythm Holdings, Inc. has entered into a definitive agreement to acquire Vital Connect, Inc. for approximately $287.5M. The acquisition expands iRhythm’s flagship Zio cardiac monitoring portfolio by adding VitalConnect’s FDA-cleared platform, which supports mobile cardiac telemetry (MCT), inpatient monitoring, and biosensors tracking up to 11 physiological parameters. Cardiac Monitoring: iRhythm Scales Biosensor Platform Across Hospital and Home SettingsiRhythm Holdings has entered into a definitive agreement to acquire privately held wearable biosensor company VitalConnect for approximately $287.5 million. “This combination represents a significant next step in iRhythm’s evolution from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and CEO of iRhythm. “VitalConnect adds complementary mobile cardiac telemetry, multi-vitals and hospital monitoring capabilities that complement Zio and meaningfully expand the categories of patients and customers we can serve.”